{
    "data": [
        {
            "id": "4477325",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-30T11:32:37-05:00",
                "isLockedPro": false,
                "commentCount": 67,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1296010669/image_1296010669.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Vs. Merck Stock: Which Is The Better Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "354950",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4477325-bristol-myers-squibb-vs-merck-stock"
            }
        },
        {
            "id": "4474051",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-08T09:33:13-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1151361649/image_1151361649.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "352185",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4474051-prometheus-biotech-to-watch"
            }
        },
        {
            "id": "4473209",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-03T09:10:02-05:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1314035412/image_1314035412.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Early Stage COVID Treatments: Merck's Molnupiravir Struggles",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "351620",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4473209-early-stage-covid-treatments-mercks-molnupiravir-struggles"
            }
        },
        {
            "id": "4472883",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-01T18:52:00-05:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1301585098/image_1301585098.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Rethinking Molnupiravir",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "351430",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4472883-rethinking-molnupiravir"
            }
        },
        {
            "id": "4472708",
            "type": "article",
            "attributes": {
                "publishOn": "2021-12-01T00:21:56-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1306384884/image_1306384884.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck Is A Buy Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "86786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "351273",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4472708-merck-stock-buy-now"
            }
        },
        {
            "id": "4472675",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-30T20:00:35-05:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184860418/image_184860418.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bargain Alert: Merck Is A Strong Buy On The Drop",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "351278",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4472675-merck-stock-a-strong-buy-on-the-drop"
            }
        },
        {
            "id": "4470842",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-20T09:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Zoom Video, Best Buy And More Electric Vehicle Jolts",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4470842-stocks-to-watch-zoom-video-best-buy-and-more-electric-vehicle-jolts"
            }
        },
        {
            "id": "4469170",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-13T03:14:53-05:00",
                "isLockedPro": false,
                "commentCount": 58,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1239519661/image_1239519661.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck's Plan B Percolates After Pfizer Announces Dominance",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22349",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "348999",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4469170-mercks-mark-plan-b-percolates-after-pfizer-announces-dominance"
            }
        },
        {
            "id": "4468501",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-11T13:46:22-05:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1207421050/image_1207421050.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How Will Merck's Stock Forecast Be Impacted By U.K.'s COVID Pill Authorization?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "348735",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4468501-merck-stock-forecast-uk-covid-pill"
            }
        },
        {
            "id": "4467241",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-09T07:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666883/image_1307666883.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck Stock Still Looks Attractive Despite Pfizer Competition",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24784",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "348397",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4467241-merck-stock-covid-pill-looks-attractive-despite-pfizer-competition"
            }
        },
        {
            "id": "4464841",
            "type": "article",
            "attributes": {
                "publishOn": "2021-11-03T08:00:23-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Energy Names With Room To Run - David Bahnsen Joins Alpha Trader (Podcast)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105447",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "579361",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4464841-energy-names-with-room-to-run-david-bahnsen-joins-alpha-trader-podcast"
            }
        },
        {
            "id": "4461819",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-25T13:51:39-04:00",
                "isLockedPro": false,
                "commentCount": 99,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1251485261/image_1251485261.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck Vs. Pfizer: Which Healthcare Stock Is The Better Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "346327",
                            "type": "sentiment"
                        },
                        {
                            "id": "346328",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4461819-merck-vs-pfizer-healthcare-stock-better-buy"
            }
        },
        {
            "id": "4461616",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-23T10:27:03-04:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Apple Earnings, Facebook Talks Metaverse And GlobalFoundries IPO",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4461616-stocks-to-watch-apple-earnings-facebook-talks-metaverse-and-globalfoundries-ipo"
            }
        },
        {
            "id": "4460901",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-20T15:34:35-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/931752622/image_931752622.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "345774",
                            "type": "sentiment"
                        },
                        {
                            "id": "345775",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4460901-atea-covid-antiviral-trial-failure-hands-initiative-to-merck"
            }
        },
        {
            "id": "4458648",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-06T06:51:39-04:00",
                "isLockedPro": false,
                "commentCount": 95,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1283195266/image_1283195266.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck Stock Up On Molnupiravir, But Don't Get Too Excited",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "344083",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4458648-merck-stock-up-on-molnupiravir-but-dont-get-too-excited"
            }
        },
        {
            "id": "4458539",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-05T13:24:44-04:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1263854264/image_1263854264.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: Do Not Buy The News",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "86786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "343887",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4458539-merck-stock-do-not-buy-the-news"
            }
        },
        {
            "id": "4458406",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-04T16:58:35-04:00",
                "isLockedPro": false,
                "commentCount": 108,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1297218922/image_1297218922.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck's Molnupiravir: If Peer Reviews Confirm Results, The Implications Would Be Massive",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106339",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "343803",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4458406-mercks-molnupiravir-could-be-massive"
            }
        },
        {
            "id": "4458390",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-04T15:19:05-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1268181219/image_1268181219.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merger Arbitrage Mondays: Merck Acquires Acceleron For $10.8 Billion",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "343820",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4458390-merger-arbitrage-mondays-merck-acquires-acceleron-for-10-8-billion"
            }
        },
        {
            "id": "4458123",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-02T07:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 94,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1296010648/image_1296010648.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "New COVID Drug Boosts Merck While Moderna And BioNTech Suffer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "343617",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4458123-new-covid-drug-boosts-merck-mrk-stock-moderna-biontech-suffer"
            }
        },
        {
            "id": "4458116",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-02T00:27:16-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Wall Street Breakfast: What Moved Markets This Week (Podcast)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25250",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "343629",
                            "type": "sentiment"
                        },
                        {
                            "id": "343628",
                            "type": "sentiment"
                        },
                        {
                            "id": "343627",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "579361",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4458116-wall-street-breakfast-what-moved-markets-this-week-podcast"
            }
        },
        {
            "id": "4458087",
            "type": "article",
            "attributes": {
                "publishOn": "2021-10-01T16:28:22-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks Rally To End Losing Week",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105763",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "343608",
                            "type": "sentiment"
                        },
                        {
                            "id": "343607",
                            "type": "sentiment"
                        },
                        {
                            "id": "343606",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4458087-stocks-rally-to-end-losing-week-month-what-moved-markets-video"
            }
        },
        {
            "id": "4456457",
            "type": "article",
            "attributes": {
                "publishOn": "2021-09-21T21:27:59-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284113909/image_1284113909.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Prometheus Biosciences: Precision Medicine For IBD",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105666",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "342207",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4456457-prometheus-biosciences-stock-precision-medicine-ibd"
            }
        },
        {
            "id": "4456255",
            "type": "article",
            "attributes": {
                "publishOn": "2021-09-21T01:26:55-04:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1257039642/image_1257039642.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck Is A Table-Pounding Buy, Here's Why",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "342189",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4456255-merck-is-a-table-pounding-buy-heres-why"
            }
        },
        {
            "id": "4453881",
            "type": "article",
            "attributes": {
                "publishOn": "2021-09-07T11:06:16-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1297651436/image_1297651436.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Forget The Downgrade, Merck's Stock May Be Ready To Surge",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71685",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "340527",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4453881-forget-the-downgrade-mercks-stock-may-be-ready-to-surge"
            }
        },
        {
            "id": "4453010",
            "type": "article",
            "attributes": {
                "publishOn": "2021-09-01T11:49:34-04:00",
                "isLockedPro": false,
                "commentCount": 33,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: Sentiment Points To A Selloff",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "86786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "339341",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4453010-merck-sentiment-points-to-selloff"
            }
        },
        {
            "id": "4451729",
            "type": "article",
            "attributes": {
                "publishOn": "2021-08-25T10:53:56-04:00",
                "isLockedPro": false,
                "commentCount": 148,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1047840476/image_1047840476.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: An Unsustainable Dividend And 2 Potential Replacements",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106141",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "338661",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4451729-merck-dividend-looks-risky"
            }
        },
        {
            "id": "4451401",
            "type": "article",
            "attributes": {
                "publishOn": "2021-08-23T21:10:36-04:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck - One Of The Best Pharma 'BUYS'",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "338585",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4451401-merck-one-of-the-best-pharma-buys"
            }
        },
        {
            "id": "4451325",
            "type": "article",
            "attributes": {
                "publishOn": "2021-08-23T13:30:56-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1297651432/image_1297651432.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck & Co.: Near Term Risks Gauged By Yield Spread",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "338542",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4451325-merck-risks-gauged-by-yield-spread"
            }
        },
        {
            "id": "4451194",
            "type": "article",
            "attributes": {
                "publishOn": "2021-08-23T03:50:19-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck - Murky Non-Keytruda Performance",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "338536",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4451194-merck-murky-non-keytruda-performance"
            }
        },
        {
            "id": "4451134",
            "type": "article",
            "attributes": {
                "publishOn": "2021-08-22T08:36:21-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1178583429/image_1178583429.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Revisiting My Johnson & Johnson Long Vs. Short Merck Call In 2020",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56142",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "338428",
                            "type": "sentiment"
                        },
                        {
                            "id": "338429",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4451134-revisiting-my-long-johnson-and-johnson-vs-short-merck-call-in-2020"
            }
        },
        {
            "id": "4440569",
            "type": "article",
            "attributes": {
                "publishOn": "2021-07-22T08:55:52-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/56293183/image_56293183.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "An Improving Outlook For Merck",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20102",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "334108",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4440569-improving-outlook-for-merck"
            }
        },
        {
            "id": "4440457",
            "type": "article",
            "attributes": {
                "publishOn": "2021-07-21T16:03:43-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/72561161/image_72561161.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck & Co.: A Wide Moat Business At A Discounted Price",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "334020",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4440457-merck-wide-moat-business-at-discounted-price"
            }
        },
        {
            "id": "4436693",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-26T00:18:22-04:00",
                "isLockedPro": false,
                "commentCount": 64,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1285261108/image_1285261108.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck Desperate To Get Back In Coronavirus Race, With A Pill",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105156",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "328791",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4436693-merck-desperate-to-get-back-in-coronavirus-race-with-a-pill"
            }
        },
        {
            "id": "4435785",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-21T08:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1224596109/image_1224596109.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "330108",
                            "type": "sentiment"
                        },
                        {
                            "id": "330110",
                            "type": "sentiment"
                        },
                        {
                            "id": "330109",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4435785-merck-ridgeback-bio-starpharma-lead-early-covid-treatment-prospects"
            }
        },
        {
            "id": "4434654",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-14T04:00:05-04:00",
                "isLockedPro": false,
                "commentCount": 61,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1283194749/image_1283194749.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Dividend Sleuthing: Merck",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40591",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "329260",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4434654-dividend-sleuthing-merck"
            }
        },
        {
            "id": "4433261",
            "type": "article",
            "attributes": {
                "publishOn": "2021-06-05T09:31:51-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Spotlight On REITs, Apple, Chewy And GameStop",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4433261-stocks-to-watch-spotlight-on-reits-apple-chewy-and-gamestop"
            }
        },
        {
            "id": "4430645",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-22T08:32:16-04:00",
                "isLockedPro": false,
                "commentCount": 93,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1209427002/image_1209427002.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck Is A Great Relative Value And A Good Absolute Value",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95006",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "326322",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4430645-merck-is-great-relative-value-and-good-absolute-value"
            }
        },
        {
            "id": "4430387",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-21T06:06:30-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck's Valuation Continues To Say 'BUY'",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "326244",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4430387-mercks-valuation-continues-to-say-buy"
            }
        },
        {
            "id": "4429666",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-18T13:06:59-04:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck's Must-Know Competitive Vulnerability",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105667",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "325805",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4429666-mercks-must-know-competitive-vulnerabilities"
            }
        },
        {
            "id": "4423073",
            "type": "article",
            "attributes": {
                "publishOn": "2021-05-01T08:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Eyes On Vaxart, Union Pacific, Honest IPO And Merck Spinoff",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4423073-stocks-to-watch-eyes-on-vaxart-union-pacific-honest-ipo-and-merck-spinoff-"
            }
        },
        {
            "id": "4421064",
            "type": "article",
            "attributes": {
                "publishOn": "2021-04-24T09:34:19-04:00",
                "isLockedPro": false,
                "commentCount": 53,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Apple, Tesla And Microsoft Lead Huge Earnings Week",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4421064-stocks-to-watch-apple-tesla-and-microsoft-lead-huge-earnings-week"
            }
        },
        {
            "id": "4419414",
            "type": "article",
            "attributes": {
                "publishOn": "2021-04-16T10:55:09-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1212869167/image_1212869167.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck Keeps Plowing On",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "321568",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4419414-merck-keeps-plowing-on"
            }
        },
        {
            "id": "4418966",
            "type": "article",
            "attributes": {
                "publishOn": "2021-04-14T00:14:40-04:00",
                "isLockedPro": false,
                "commentCount": 86,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/492444164/image_492444164.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons Warren Buffett Loves Merck",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "320969",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4418966-merck-3-reasons-warren-buffett-loves-it"
            }
        },
        {
            "id": "4418211",
            "type": "article",
            "attributes": {
                "publishOn": "2021-04-08T14:56:14-04:00",
                "isLockedPro": false,
                "commentCount": 62,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck & Co. Is Flatlined But Watch For Its Revival",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "62873",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "319974",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4418211-merck-co-is-flatlined-watch-for-revival"
            }
        },
        {
            "id": "4417726",
            "type": "article",
            "attributes": {
                "publishOn": "2021-04-05T21:43:13-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1208007386/image_1208007386.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Acceleron: Neutral On Stock Price Gains",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "320160",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4417726-acceleron-neutral-on-stock-price-gains"
            }
        },
        {
            "id": "4415442",
            "type": "article",
            "attributes": {
                "publishOn": "2021-03-23T10:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 50,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1306382386/image_1306382386.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buffett Favorite Merck Gets A Coronavirus Kicker",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "318210",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4415442-buffett-favorite-merck-gets-coronavirus-kicker"
            }
        },
        {
            "id": "4414000",
            "type": "article",
            "attributes": {
                "publishOn": "2021-03-15T12:20:23-04:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: When Cash Flow Meets Valuation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80836",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "317238",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4414000-merck-stock-when-cash-flow-meets-valuation"
            }
        },
        {
            "id": "4413689",
            "type": "article",
            "attributes": {
                "publishOn": "2021-03-13T09:16:00-05:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Nike, FedEx, Rising Yield Plays And A Sports ETF",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4413689-stocks-to-watch-nike-fedex-rising-yield-plays-and-a-sports-etf"
            }
        },
        {
            "id": "4413399",
            "type": "article",
            "attributes": {
                "publishOn": "2021-03-12T03:10:18-05:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Assessing The Strength Of Merck's Dividend",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "67113",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "316842",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4413399-assessing-strength-of-merck-s-dividend"
            }
        },
        {
            "id": "4412342",
            "type": "article",
            "attributes": {
                "publishOn": "2021-03-08T18:37:28-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "IPO Update: Prometheus Biosciences Lights Fire On $125 Million IPO",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101421",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "316460",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4412342-ipo-update-prometheus-biosciences-lights-fire-on-125-million-ipo"
            }
        },
        {
            "id": "4409134",
            "type": "article",
            "attributes": {
                "publishOn": "2021-02-25T16:53:43-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Prometheus Biosciences Starts $125 Million IPO Plan",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101421",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "314966",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4409134-prometheus-biosciences-starts-125-million-ipo-plan"
            }
        },
        {
            "id": "4405679",
            "type": "article",
            "attributes": {
                "publishOn": "2021-02-12T10:06:42-05:00",
                "isLockedPro": false,
                "commentCount": 74,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: Positioned To Deliver For Dividend Investors In 2021",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105646",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "312870",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4405679-merck-positioned-to-deliver-for-dividend-investors-in-2021"
            }
        },
        {
            "id": "4404211",
            "type": "article",
            "attributes": {
                "publishOn": "2021-02-07T23:46:04-05:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Analysts Think The Market Is All Wrong On Merck",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20102",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "312387",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4404211-analysts-think-market-is-all-wrong-on-merck"
            }
        },
        {
            "id": "4399368",
            "type": "article",
            "attributes": {
                "publishOn": "2021-01-17T10:50:55-05:00",
                "isLockedPro": false,
                "commentCount": 81,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Among The Dogs Of The DOW, Merck Is The Best Of Breed",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "59101",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "308755",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4399368-among-dogs-of-dow-merck-is-best-of-breed"
            }
        },
        {
            "id": "4397128",
            "type": "article",
            "attributes": {
                "publishOn": "2021-01-04T04:49:08-05:00",
                "isLockedPro": false,
                "commentCount": 111,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck's Recent Acquisition Highlights OWS Funding Flowing Into COVID-19 Therapeutics",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104723",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "307136",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4397128-mercks-recent-acquisition-highlights-ows-funding-flowing-covidminus-19-therapeutics"
            }
        }
    ]
}